The $400,000 SBIR Phase I award will support the further development of Tiba’s targeted delivery platform for a range of inflammatory lung diseases.
Tiba Biotech Announces Strategic Collaboration with CVIM to Advance RNA-Based Livestock Vaccines
April 9, 2026
Tiba announces strategic collaboration with Pirbright’s CVIM to accelerate the development of next-generation RNA vaccines targeting high-impact livestock diseases using the RNABL™ delivery platform.
Vaccine Breakthrough for Global Livestock Diseases
October 28, 2025
Tiba Biotech has announced a major scientific milestone with the development of the world’s first RNA vaccine against Foot-and-Mouth Disease (FMD). This achievement was recently featured on Landline, the Australian Broadcasting Corporation’s flagship program covering rural and regional affairs.
Tiba Biotech Receives NCI Grant to Advance Next-Generation RNA Cancer Immunotherapies
September 25, 2025
The $400,000 SBIR Phase I award will support development of Tiba’s tissue-targeted delivery platform and proprietary enhanced self-amplifying RNA payloads.
Tiba announced the results of a challenge study evaluating the efficacy of a novel vaccine for Foot and Mouth Disease (FMD) in cattle using Tiba’s RNABL™ delivery platform.
BARDA highlights Tiba in a new FASTx program to accelerate the development of early-stage antiviral platforms with multiple collaborators
Tiba announces a BARDA FASTx award to develop an RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein using Tiba’s novel RNABL™ delivery platform
The government of NSW (Australia) is investing in a range of animal disease vaccines with leading institutions and technology providers, including Tiba Biotech. A pilot project intended to fast-track an mRNA vaccine for border disease virus (BDV) has been successfully manufactured for the first time in NSW.
Tiba Biotech has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and Development Authority (‘BARDA’), to apply our next-generation nucleic acid delivery technology to develop new products that can guard against and respond to public health threats.
CEPI highlights progress toward a new generation of vaccines
January 15, 2024
Tiba Biotech was mentioned in the recent edition of THE VIRAL MOST WANTED, a series of articles by the Coalition for Epidemic Preparedness Innovations (CEPI), highlighting progress toward the development of next generation flavivirus vaccines.
Keep connected with us
© 2026 Tiba Biotech LLC. All rights reserved